

Çetin Kürşad AKPINAR¹

Adnan Burak BİLGİÇ²

1. COVID 19 hastalığına bağlı nörolojik bulguları nasıl ortaya çıkar?
2. COVID 19 tanılı hastalarda nörolojik muayene nasıl yapılır, nelere dikkat etmeliyiz?
3. COVID 19 tanılı hastalarda nörolojik semptom görülme sıklığı nedir ve hangi nörolojik semptomlar görülebilir?
4. COVID 19 tanılı hastalarda nörolojik semptomlar hangi mekanizmalarla gelişmektedir?
5. Pandemi süresince elektroensefalografi (EEG) kimlere istenmeli ve nelere dikkat etmek gerekir?
6. Pandemi süresince elektromiyografi (EMG) kimlere istenmeli ve nelere dikkat etmek gerekir?
7. Pandemi nörolojik acil hastalıkların sıklığında artma oldu mu bu, acil hastaların yönetimi nasıl olmalıdır, ilaç kullanımında nelere dikkat edilmelidir?
8. Nörolojik hastalıklarda kullanılan ilaçların COVID 19 tedavisinde kullanılan ilaçlarla bir etkileşimi var mı? kimlere istenmeli ve nelere dikkat etmek gerekir?

¹ Prof. Dr. Çetin Kürşad AKPINAR, Sağlık Bilimleri Üniversitesi, Samsun Eğitim ve Araştırma Hastanesi, Nöroloji Bölümü, İnme Merkezi, dr_ckakpinar@hotmail.com

² Uzm. Dr. Adnan Burak BİLGİÇ, Sağlık Bilimleri Üniversitesi, Samsun Eğitim ve Araştırma Hastanesi, Nöroloji Bölümü, İnme Merkezi, aburakbilgic@hotmail.com

lamatuvar markerları yüksek olan hastalarda düşük molekül ağırlıklı heparin ve antiagregan kullanımı önemlidir.

KAYNAKLAR:

1. Zhou Y, Li W, Wang D, et al. Clinical Time Course of COVID-19, Its Neurological Manifestation and Some Thoughts on Its Management. *Stroke Vasc Neurol.* 2020;4:1-3.
2. Mao L, Jin H, Wang M, et al. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. *JAMA Neurol.* 2020;77:683-690.
3. Ahmad I, Rathore FA. Neurological Manifestations and Complications of COVID-19: A Literature Review. *J Clin Neurosci.* 2020;77:8-12.
4. Pascarella G, Strumia A, Pilegio C, et al. COVID-19 diagnosis and management: a comprehensive review. *J Intern Med.* 2020;288:192-206.
5. Moro E, Priori A, Beghi E, et al; EAN core COVID-19 Task Force. The international European Academy of Neurology survey on neurological symptoms in patients with COVID-19 infection. *Eur J Neurol.* 2020;27:1727-1737.
6. Moriguchi T, Harii N, Goto J, et al. A first case of meningitis/encephalitis associated with SARS-Coronavirus-2. *Int J Infect Dis.* 2020;94:55-58.
7. Baig AM. Neurological manifestations in COVID-19 caused by SARS-CoV-2. *CNS Neurosci Ther* 2020;26:499-501.
8. Poyiadji N, Shahin G, Noujaim D, et al. COVID-19-associated Acute Hemorrhagic Necrotizing Encephalopathy: CT and MRI Features. *Radiology.* 2020:201187.
9. Mao L, Jin H, Wang M, et al. Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China. *JAMA Neurol.* 2020;77:683-690.
10. Tan YK, Goh C, Leow AST, et al. COVID-19 and ischemic stroke: a systematic review and meta-summary of the literature. *J Thromb Thrombolysis.* 2020;50:587-595.
11. Merkler AE, Parikh NS, Mir S, et al. Risk of Ischemic Stroke in Patients With Coronavirus Disease 2019 (COVID-19) vs Patients With Influenza. *JAMA Neurol.* 2020;77:1-7
12. Yaghi S, Ishida K, Torres J, et al. SARS-CoV-2 and Stroke in a New York Healthcare System. *Stroke.* 2020;51:2002-2011.
13. Mao L, Jin H, Wang M, et al. Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China. *JAMA Neurol.* 2020;77:683-690.
14. Chen T, Wu D, Chen H, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. *BMJ.* 2020;368:1091
15. Filatov A, Sharma P, Hindi F et al. Neurological complications of coronavirus disease (COVID-19): encephalopathy. *Cureus* 2020;12(3):e7352.
16. Acar T, Acıman Demirel E, Afşar N, et al. The COVID-19 from Neurological Overview *Turk J Neurol.* 2020;26:56-106
17. Wu Y, Xu X, Chen Z, et al. Nervous system involvement after infection with COVID-19 and other coronaviruses. *Brain Behav Immun.* 2020;S0889- 1591.
18. To KF, Tong JH, Chan PK, et al. Tissue and cellular tropism of the coronavirus associated with severe acute respiratory syndrome: an in-situ hybridization study of fatal cases. *J Pathol.* 2004;202:157-163.
19. Jin H, Hong C, Chen S, et al. Consensus for prevention and management of coronavirus disease 2019 (COVID-19) for neurologists. *Stroke Vasc Neurol.* 2020;5:146-151.
20. Spence JD, de Freitas GR, Pettigrew LC, et al. Mechanisms of Stroke in COVID-19. *Cerebrovasc Dis.* 2020;49:451-458.
21. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet.* 2020;395:507-513.
22. Toscano G, Palmerini F, Ravaglia S, et al. Guillain-Barre Syndrome Associated with SARS-CoV-2. *N Engl J Med.* 2020;382:2574-2576.

23. Novi G, Mikulska M, Briano F, et al. COVID-19 in a MS patient treated with ocrelizumab: does immunosuppression have a protective role? *Mult Scler Relat Disord.* 2020;42:102120.
24. Oxley TJ, Mocco J, Majidi S, et al. Large-Vessel Stroke as a Presenting Feature of COVID-19 in the Young. *N Engl J Med.* 2020;382:e60.
25. Cortegiani A, Ingoglia G, Ippolito M, et al. A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. *J Crit Care.* 2020;57:279-283.
26. Birbeck GL, French JA, Perucca E, et al. Antiepileptic drug selection for people with HIV/AIDS: evidence-based guidelines from the ILAE and AAN. *Epilepsia.* 2012;53:207-214.
27. Patsalos PN, Berry DJ, Bourgeois BF, et al. Antiepileptic drugs-best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. *Epilepsia.* 2008;49:1239-1276.
28. Aktöz M, Altay H, Aslanger E, et al. [Consensus Report from Turkish Society of Cardiology: COVID-19 and Cardiovascular Diseases. What cardiologists should know. (25th March 2020)]. *Turk Kardiyol Dern Ars* 2020;48(Suppl 1):1-48.
29. Şimşek YS, Ünal S. Antiviral treatment of COVID-19. *Turk J Med Sci.* 2020;50(Suppl 1):611-619.